Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)

Whitehawk Therapeutics (WHWK) has 5 years of Gross Margin data on file, last reported at 89.36% in Q1 2025.

• On a quarterly basis, Gross Margin rose 154.0% year-over-year to 89.36% in Q1 2025; TTM through Dec 2025 was 89.36%, a 100.0% increase from a year earlier, with the FY2025 full-year figure at 89.36%, up 100.0% from the prior year.
• Gross Margin for Q1 2025 stood at 89.36%, roughly flat from 89.09% in the prior quarter.
• Over the last five years, Gross Margin for WHWK reached as high as 100.0% in Q4 2021 and fell as low as 85.35% in Q4 2023.
• Historically, Gross Margin has averaged 90.05% across 5 years, with a median of 89.23% in 2024.
• Across the five-year window, Gross Margin tumbled 1041 bps in 2023 and jumped 374 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 100.0% in 2021, then dropped by 4 bps to 95.75% in 2022, then decreased by 11 bps to 85.35% in 2023, then advanced by 4 bps to 89.09% in 2024, then increased by 0 bps to 89.36% in 2025.
• Per Business Quant data, the three most recent Gross Margin figures were 89.36% in Q1 2025, 89.09% in Q4 2024, and 88.85% in Q3 2024.